Virulence Phenotypes Differentiate Persistent vs. Resolving Isolates of Human Staphylococcus aureus Bacteremia
Antibiotics · 25.03.2026 · 15 (4) · 332
DOI: 10.3390/antibiotics15040332 ↗Kurz gefasst
Fachartikel in der Zeitschrift Antibiotics, online erschienen am 25.03.2026. Verfasst von Liana C Chan und 15 weiteren Autor:innen. Beteiligte Einrichtung: Harbor-UCLA Medical Center, Division of Molecular Medicine, Torrance, CA 90502, USA. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 93 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCATS NIH HHS, NIAID NIH HHS, U.S. National Institutes of Health.
Abstract (Originalsprache)
Background
Staphylococcus aureus bacteremia (SAB) is a common and life-threatening bloodstream infection often caused by methicillin-resistant SA (MRSA) isolates. Up to 35% of SAB patients fail to clear infection with gold-standard anti-MRSA antibiotics, even if the isolate meets susceptibility breakpoints in conventional assays in vitro. Such outcomes are termed persistent and may involve small colony variant (SCV) adaptation of SA in vivo.
Methods
In this study, we assessed virulence phenotypes and mechanisms in persistent (PB) vs. resolving (RB) MRSA isolates from SAB.
Results
Overall, PB isolates caused less hemolysis or biofilm formation than RB isolates, but proteolysis was equivalent. Attenuation of these virulence phenotypes increased longitudinally during the course of SAB. Although PB vs. RB isolates had similar human endothelial cell invasion rates, PB isolates more frequently formed SCVs intracellularly and inversely correlated with pH. Study PB and RB isolates exhibited distinct susceptibilities to prototypic human host defense peptides (HDPs), which were influenced by antibiotics and pH. Furthermore, mechanistic signatures of HDPs differed between PB and RB isolates.
Conclusions
Together, these results reveal that MRSA isolates from PB vs. RB outcomes of SAB have differential virulence profiles that suggest coordinated immune subversion in PB. Understanding MRSA adaptations that promote persistence in SAB may enable innovative agents and strategies to address these challenging infections.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Harbor-UCLA Medical Center, Division of Molecular Medicine, Torrance, CA 90502, USA.
- Harbor-UCLA Medical Center, Division of Infectious Diseases, Torrance, CA 90502, USA.
- Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA 90024, USA.
- The Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Institute for Infection and Immunity, Torrance, CA 90502, USA.
- Division of Infectious Diseases and International Health, Department of Medicine, Duke University School of Medicine, Durham, NC 27708, USA.
- Duke Clinical Research Institute, Durham, NC 27708, USA.
ORCID-Profile: Liana C Chan, Felicia Ruffin, Arnold S Bayer
Förderung
- NCATS NIH HHS
- NIAID NIH HHS
- U.S. National Institutes of Health
- University of California, Los Angeles
Zitieren
APA
Chan, L. C., Lee, H. K., Wang, L., Wang, H., Filler, S. G., Ciranna, A., Abdelhady, W., Xiong, Y. Q., Li, L., Gonzales, R. A., Ruffin, F., Fowler, V. G., Bayer, A. S., Proctor, R. A., Yeaman, M. R., & MRSA Systems Immunobiology Group (MSIG) (2026). Virulence Phenotypes Differentiate Persistent vs. Resolving Isolates of Human Staphylococcus aureus Bacteremia. Antibiotics, 15(4), 332. https://doi.org/10.3390/antibiotics15040332
Vancouver
Chan LC, Lee HK, Wang L, Wang H, Filler SG, Ciranna A, et al. Virulence Phenotypes Differentiate Persistent vs. Resolving Isolates of Human Staphylococcus aureus Bacteremia. Antibiotics. 2026;15(4):332. doi:10.3390/antibiotics15040332
BibTeX
@article{Chan2026,
author = {Chan, Liana C and Lee, Hong K and Wang, Ling and Wang, Huiyuan and Filler, Scott G and Ciranna, Alexandra and Abdelhady, Wessam and Xiong, Yan Q and Li, Liang and Gonzales, Rachelle A and Ruffin, Felicia and Fowler, Vance G and Bayer, Arnold S and Proctor, Richard A and Yeaman, Michael R and MRSA Systems Immunobiology Group (MSIG), MRSA Systems Immunobiology Group (MSIG)},
title = {Virulence Phenotypes Differentiate Persistent vs. Resolving Isolates of Human Staphylococcus aureus Bacteremia},
journal = {Antibiotics},
year = {2026},
volume = {15},
number = {4},
pages = {332},
doi = {10.3390/antibiotics15040332}
}
EUVIMED